Network


Latest external collaboration on country level. Dive into details by clicking on the dots.

Hotspot


Dive into the research topics where Francois Bretin is active.

Publication


Featured researches published by Francois Bretin.


Bioorganic & Medicinal Chemistry Letters | 1999

Synthesis and antibacterial activity of HMR 3647 a new ketolide highly potent against erythromycin-resistant and susceptible pathogens.

Alexis Denis; Constantin Agouridas; Jean-Michel Auger; Yannick Benedetti; Alain Bonnefoy; Francois Bretin; Jean-Francois Chantot; Arlette Dussarat; Claude Fromentin; Solange Gouin d'Ambrieres; Sylvette Lachaud; Patrick Laurin; Odile Le Martret; Véronique Loyau; Nicole Tessot; Jean-Marie Pejac; Sébastien Perron

In the search for new ketolides with improved activities against erythromycin-resistant S. pneumoniae and H. influenzae we synthesized a new 11,12 carbamate ketolide substituted by an imidazo-pyridyl side chain: HMR 3647. This compound demonstrated a potent activity against erythromycin susceptible and resistant pathogens, including penicillin G/erythromycin A-resistant S. pneumoniae and H. influenzae. In vivo, HMR 3647 displayed good pharmacokinetic parameters (Cmax = 2.9 microg/ml, bioavailability=49%, AUC0.8 = 17.2 microg.h/l, t1/2=1h) and was shown to have a high therapeutic efficacy in mice infected by various respiratory pathogens, including multi-resistant S. pneumoniae and Gram negative bacteria such as H. influenzae. HMR 3647 appears to be a very promising agent for the treatment of respiratory infections and is currently in clinical trials.


Bioorganic & Medicinal Chemistry Letters | 2000

β-Keto-ester chemistry and ketolides. synthesis and antibacterial activity of 2-halogeno, 2-methyl and 2,3 enol-ether ketolides

Alexis Denis; Francois Bretin; Claude Fromentin; A Bonnet; Alain Bonnefoy; Constantin Agouridas; G Piltan

The effect of 2,3 modifications on the antibacterial activity of ketolides was evaluated by introducing substituents in position 2 and converting the C-1, C-2, C-3 beta-keto-ester into stable 2,3 enol-ether or 2,3 anhydro derivatives. Introduction of a fluorine in C-2 is beneficial with regard to the overall antibacterial spectrum whereas the enol-ether and 2,3 unsaturated compounds, as well as the bulky gem dimethyl or 2-chloro derivatives, are less active particularly against erythromycin resistant strains. A 2-fluoro ketolide derivative demonstrates good antibacterial activity and in vivo efficacy against multi-resistant Streptococcus pneumoniae. Compared to azithromycin against Haemophilus influenzae, this compound is equivalent in vitro and slightly more active in vivo. These results demonstrate that within the ketolide class, to retain good antibacterial activity, position 2 needs to remain tetrahedral and tolerates only very small substituents such as fluorine.


Bioorganic & Medicinal Chemistry | 2003

Synthesis of 9-oxime-11,12-carbamate ketolides through a novel N-deamination reaction of 11,12-hydrazonocarbamate ketolide.

Alexis Denis; Jean-Marie Pejac; Francois Bretin; Alain Bonnefoy

A series of 9-oxime-11,12-carbamate ketolides was synthesized for the first time through a key 11,12-hydrazonocarbamate intermediate that was first oximated and further deaminated to give the corresponding carbamate. The N-N bond cleavage was achieved through an original new reaction using glycoaldehyde dimer as deaminating reagent. The new compounds synthesized were shown to display improved antibacterial activities against Streptococcus pneumoniae and S. pyogenes resistant to erythromycin.


Journal of Medicinal Chemistry | 1998

Synthesis and Antibacterial Activity of Ketolides (6-O-Methyl-3-oxoerythromycin Derivatives): A New Class of Antibacterials Highly Potent Against Macrolide-Resistant and -Susceptible Respiratory Pathogens†

Constantin Agouridas; Alexis Denis; Jean-Michel Auger; Yannick Benedetti; Alain Bonnefoy; Francois Bretin; Jean-Francois Chantot; Arlette Dussarat; Claude Fromentin; Solange Gouin d'Ambrieres; Sylvette Lachaud; Patrick Laurin; Odile Le Martret; and Véronique Loyau; Nicole Tessot


Archive | 1996

Erythromycin derivatives, their production and their use as medicaments

Constantin Agouridas; Francois Bretin; Jean-Francois Chantot


Archive | 2002

2-halogenated derivatives of 5-0-desosaminyl-erythronolide A, their preparation process and their antibiotic use

Constantin Agouridas; Francois Bretin; Alexis Denis; Claude Fromentin


Archive | 1995

New erythromycin derivatives

Constantin Agouridas; Francois Bretin; Jean Francois Chantot


Archive | 1999

New 2-halogenated derivatives of 5-O-deosaminylerythronolide A, process for making them as well as their use as medicines

Constantin Agouridas; Francois Bretin; Alexis Denis; Claude Fromentin


Archive | 1999

5―デスオサミニルエリスロノリドaの新規の2―ハロゲン化誘導体、それらの製造方法及び薬剤としてのそれらの使用

Constantin Agouridas; Francois Bretin; Alexis Denis; Claude Fromentin; アレクシー・ドニ; クロード・フロマンタン; コンスタンタン・アグリーダ; フランソワ・ブルタン


Archive | 1999

Neue 2-Halogen-Derivate von 5-O-Desosaminylerythronolid A, Verfahren zu deren Herstellung sowie deren Verwendung als Arzneimittel New 2-halo derivatives of 5-O-desosaminylerythronolide A, process for their preparation and their use as medicaments

Constantin Agouridas; Alexis Denis; Francois Bretin; Claude Fromentin

Collaboration


Dive into the Francois Bretin's collaboration.

Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Researchain Logo
Decentralizing Knowledge